5-Fluoro-AET


5-Fluoro-AET, also known as 5-fluoro-α-ethyltryptamine or by the code name PAL-545, is a substituted tryptamine derivative which acts as a serotonin–dopamine releasing agent and as an agonist of the serotonin 5-HT2A receptor.

Pharmacology

Pharmacodynamics

Its values for monoamine release are 36.6nM for serotonin, 5,334nM for norepinephrine, and 150nM for dopamine in rat brain synaptosomes. Its at the serotonin 5-HT2A receptor is 246nM and its at the receptor is 87%.
Several close analogues of 5-fluoro-αET, including 5-fluoro-αMT and 5-chloro-αMT, are known to be potent monoamine oxidase inhibitors, specifically of monoamine oxidase A. However, α-ethyltryptamine is a very weak MAOI. 5-Fluoro-αET has also more recently been assessed, and in contrast to αET, but similarly to drugs like 5-fluoro-αET, was found to be a potent MAOI, with an of 2,480nM. Potent monoamine oxidase inhibition by monoamine releasing agents has been associated with dangerous and sometimes fatal toxicity in humans.

Chemistry

Analogues

Analogues of 5-fluoro-AET include α-ethyltryptamine, 5-fluorotryptamine, 4-methyl-AET, 5-chloro-AET, 5-chloro-AMT, 5-fluoro-AMT, 5-fluoro-DMT, bretisilocin, 5-MeO-AET, 6-fluoro-AMT, 7-chloro-AMT, 7-methyl-DMT, and 7-methyl-AET, among others.

Society and culture

Legal status

Canada

5-Fluoro-AET is not an explicitly nor implicitly controlled substance in Canada as of 2025.

United States

5-Fluoro-AET is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.